Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates.
Alleles
Angiotensin II
/ toxicity
Animals
Antibodies
/ immunology
Aortic Aneurysm, Abdominal
/ metabolism
Biomarkers
/ metabolism
Disease Models, Animal
Humans
Interleukin-6
/ blood
Linear Models
Mice
Polymorphism, Single Nucleotide
Receptors, Interleukin-6
/ genetics
Signal Transduction
Survival Rate
Transforming Growth Factor beta
/ immunology
alleles
aortic aneurysm
genetics
inflammation
interleukins
Journal
Circulation. Genomic and precision medicine
ISSN: 2574-8300
Titre abrégé: Circ Genom Precis Med
Pays: United States
ID NLM: 101714113
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
19
1
2019
medline:
9
4
2020
entrez:
19
1
2019
Statut:
ppublish
Résumé
The Asp358Ala variant (rs2228145; A>C) in the IL (interleukin)-6 receptor ( IL6R) gene has been implicated in the development of abdominal aortic aneurysms (AAAs), but its effect on AAA growth over time is not known. We aimed to investigate the clinical association between the IL6R-Asp358Ala variant and AAA growth and to assess the effect of blocking the IL-6 signaling pathway in mouse models of aortic aneurysm rupture or dissection. Using data from 2863 participants with AAA from 9 prospective cohorts, age- and sex-adjusted mixed-effects linear regression models were used to estimate the association between the IL6R-Asp358Ala variant and annual change in AAA diameter (mm/y). In a series of complementary randomized trials in mice, the effect of blocking the IL-6 signaling pathways was assessed on plasma biomarkers, systolic blood pressure, aneurysm diameter, and time to aortic rupture and death. After adjusting for age and sex, baseline aneurysm size was 0.55 mm (95% CI, 0.13-0.98 mm) smaller per copy of the minor allele [C] of the Asp358Ala variant. Change in AAA growth was -0.06 mm per year (-0.18 to 0.06) per copy of the minor allele; a result that was not statistically significant. Although all available worldwide data were used, the genetic analyses were not powered for an effect size as small as that observed. In 2 mouse models of AAA, selective blockage of the IL-6 trans-signaling pathway, but not combined blockage of both, the classical and trans-signaling pathways, was associated with improved survival ( P<0.05). Our proof-of-principle data are compatible with the concept that IL-6 trans-signaling is relevant to AAA growth, encouraging larger-scale evaluation of this hypothesis.
Sections du résumé
BACKGROUND
The Asp358Ala variant (rs2228145; A>C) in the IL (interleukin)-6 receptor ( IL6R) gene has been implicated in the development of abdominal aortic aneurysms (AAAs), but its effect on AAA growth over time is not known. We aimed to investigate the clinical association between the IL6R-Asp358Ala variant and AAA growth and to assess the effect of blocking the IL-6 signaling pathway in mouse models of aortic aneurysm rupture or dissection.
METHODS
Using data from 2863 participants with AAA from 9 prospective cohorts, age- and sex-adjusted mixed-effects linear regression models were used to estimate the association between the IL6R-Asp358Ala variant and annual change in AAA diameter (mm/y). In a series of complementary randomized trials in mice, the effect of blocking the IL-6 signaling pathways was assessed on plasma biomarkers, systolic blood pressure, aneurysm diameter, and time to aortic rupture and death.
RESULTS
After adjusting for age and sex, baseline aneurysm size was 0.55 mm (95% CI, 0.13-0.98 mm) smaller per copy of the minor allele [C] of the Asp358Ala variant. Change in AAA growth was -0.06 mm per year (-0.18 to 0.06) per copy of the minor allele; a result that was not statistically significant. Although all available worldwide data were used, the genetic analyses were not powered for an effect size as small as that observed. In 2 mouse models of AAA, selective blockage of the IL-6 trans-signaling pathway, but not combined blockage of both, the classical and trans-signaling pathways, was associated with improved survival ( P<0.05).
CONCLUSIONS
Our proof-of-principle data are compatible with the concept that IL-6 trans-signaling is relevant to AAA growth, encouraging larger-scale evaluation of this hypothesis.
Identifiants
pubmed: 30657332
doi: 10.1161/CIRCGEN.118.002413
pmc: PMC6383754
mid: EMS81360
doi:
Substances chimiques
Antibodies
0
Biomarkers
0
IL6R protein, human
0
Interleukin-6
0
Receptors, Interleukin-6
0
Transforming Growth Factor beta
0
Angiotensin II
11128-99-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e002413Subventions
Organisme : Medical Research Council
ID : MR/L003120/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/12/33270
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CS/14/2/30841
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/18/13/33946
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/13/30194
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/15/11/31593
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/79120
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/79915
Pays : United Kingdom
Références
Br J Surg. 2016 Aug;103(9):1097-104
pubmed: 27346306
JAMA. 2013 Feb 27;309(8):806-13
pubmed: 23443444
Int J Rheumatol. 2010;2010:720305
pubmed: 20981316
Circulation. 2011 Sep 6;124(10):1118-23
pubmed: 21844079
J Clin Invest. 2010 Feb;120(2):422-32
pubmed: 20101093
BMJ. 2005 Apr 2;330(7494):750
pubmed: 15757960
Biochim Biophys Acta. 2014 Sep;1842(9):1485-94
pubmed: 24878322
N Engl J Med. 2017 Nov 9;377(19):1894-1896
pubmed: 29117496
Int J Hematol. 2009 Jul;90(1):99-102
pubmed: 19554396
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2171-2181
pubmed: 28912363
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2605-13
pubmed: 16973970
Nature. 2012 Aug 23;488(7412):508-511
pubmed: 22801493
Lancet. 2011 Sep 10;378(9795):1006-14
pubmed: 21907864
Lancet. 2005 Apr 30-May 6;365(9470):1577-89
pubmed: 15866312
Lancet. 2008 Mar 22;371(9617):987-97
pubmed: 18358926
Nat Genet. 2016 Oct;48(10):1151-1161
pubmed: 27618447
Nat Genet. 2012 Dec;44(12):1336-40
pubmed: 23143596
Circulation. 2008 Dec 2;118(23):2382-92
pubmed: 19047592
Cytokine. 2009 May;46(2):211-5
pubmed: 19251434
Eur J Vasc Endovasc Surg. 2009 Dec;38(6):748-9
pubmed: 19666232
Circulation. 2004 Jul 6;110(1):16-21
pubmed: 15210603
Eur J Vasc Endovasc Surg. 2013 Oct;46(4):453-9
pubmed: 23978561
J Immunol. 2008 Jun 1;180(11):7102-6
pubmed: 18490707
Cochrane Database Syst Rev. 2015 Feb 08;(2):CD001835
pubmed: 25927098
Nat Rev Cardiol. 2017 Aug;14(8):457-471
pubmed: 28406184
Ann Intern Med. 1995 Apr 1;122(7):502-7
pubmed: 7872584
Nat Rev Drug Discov. 2018 Jun;17(6):395-412
pubmed: 29725131
Crit Care Med. 2011 Jun;39(6):1407-13
pubmed: 21336117
PLoS Genet. 2013 Apr;9(4):e1003444
pubmed: 23593036
Eur Heart J. 2013 Dec;34(48):3707-16
pubmed: 23111417
J Vasc Surg. 2009 Jan;49(1):178-84
pubmed: 18829218
Nat Rev Cardiol. 2009 Aug;6(8):543-52
pubmed: 19546866
Am J Hum Genet. 2011 Nov 11;89(5):619-27
pubmed: 22055160
Circ Cardiovasc Genet. 2017 Oct;10(5):
pubmed: 28986451
J Clin Invest. 2013 Mar;123(3):1019-31
pubmed: 23426178
Nat Rev Cardiol. 2011 Feb;8(2):92-102
pubmed: 21079638
Atherosclerosis. 2011 Jul;217(1):57-63
pubmed: 21596379
Clin Rheumatol. 2016 Nov;35(11):2657-2661
pubmed: 27502778
Br J Surg. 2009 Aug;96(8):870-7
pubmed: 19591171
JAMA Intern Med. 2016 Dec 1;176(12):1761-1767
pubmed: 27802493
Nat Rev Rheumatol. 2017 Jul;13(7):399-409
pubmed: 28615731
Eur J Cell Biol. 2011 Jun-Jul;90(6-7):484-94
pubmed: 21145125
Lancet. 2012 Mar 31;379(9822):1205-13
pubmed: 22421339
Circ Cardiovasc Genet. 2011 Oct;4(5):557-64
pubmed: 21846873
PLoS One. 2016 Jan 19;11(1):e0147088
pubmed: 26783750
Circulation. 2005 Jun 14;111(23):3119-25
pubmed: 15939823